Could Athenex Inc (NASDAQ:ATNX) Skyrocket? The Stock Had Too Little Sellers

May 17, 2018 - By Marie Mckinney

The stock of Athenex Inc (NASDAQ:ATNX) registered a decrease of 2.6% in short interest. ATNX’s total short interest was 2.70 million shares in May as published by FINRA. Its down 2.6% from 2.77 million shares, reported previously. With 116,800 shares average volume, it will take short sellers 23 days to cover their ATNX’s short positions. The short interest to Athenex Inc’s float is 10.46%.

The stock increased 0.42% or $0.07 during the last trading session, reaching $16.83. About 143,964 shares traded. Athenex, Inc. (NASDAQ:ATNX) has 0.00% since May 17, 2017 and is . It has underperformed by 11.55% the S&P500.

Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of cancer. The company has market cap of $1.07 billion. The Company’s Orascovery product candidates include Oraxol, an oral dosage form, which is in a Phase III trial in metastatic breast cancer for the treatment of advanced gastric cancer; Oratecan, an anticancer agent that is in a Phase 1 study for the treatment of colorectal, lung, ovarian, cervical, pancreatic, upper gastrointestinal, and brain cancer; Oradoxel, an anticancer agent, which is in a Phase 1 clinical study in the treatment of breast, prostate, gastric, head and neck, and lung cancer; and Oratopo, an anticancer for the treatment of cervical, ovarian ,and lung cancer. It currently has negative earnings. The firm also develops KX-01, a compound, which is in Phase 3 study for the treatment of for actinic keratosis; and KX-02 for the treatment of gliomas.

More important recent Athenex, Inc. (NASDAQ:ATNX) news were published by: which released: “Athenex (ATNX) Announces US FDA Orphan Drug Designation for Oraxol for Treatment of Angiosarcoma” on April 19, 2018, also published article titled: “Athenex’s (ATNX) CEO, Johnson Lau on Q1 2018 Results – Earnings Call Transcript”, published: “Athenex, Inc. Announces First Quarter 2018 Results” on May 14, 2018. More interesting news about Athenex, Inc. (NASDAQ:ATNX) was released by: and their article: “Athenex, Inc. Announces Transition of James Zukin from Board of Directors to Advisory Role” with publication date: April 30, 2018.

Athenex, Inc. (NASDAQ:ATNX) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.